Combination therapies with PI3K inhibition have been shown to enhance the effect of MEK inhibition within basal subtype breast cancer cells by alleviating the compensatory activation of PI3K/AKT that occurs with MEK inhibition [109]. This evidence concerns the gene AKT1 and breast cancer.